鳖甲煎丸联合恩替卡韦抗肝纤维化疗效观察

摘要

Objective:To evaluate the efficacy of Biejiajian pill against liver fibrosis in patients with chronic hepatitis B-related liver fi-brosis,and to provide more reference for clinical application.Methods:Fourty-seven patients with liver firosis were included in the Depart-ment of Infection Diseaes of Wuhan Union Hospital according to a certain inclusion and exclusion criteria.The patients were divided into the entecavir combined Biejiajian pills research group and the entecavir control group according to the random principle.The liver function and 1 iver stiffness measurement LSM were collected to analyze before and after treatment for half a year.Results:The indexes of TB,ALT and ALB of the two groups were improved after treatment(P＜0.05).But these indicators of the two groups after treatment have no statistically difference when they compared each other(P＞0.05).After treatment,the decrease of LSM in the study group was better than that in the control group,the difference was statistically significant(P＜0.05).Conclusion:The combination of Biejiajian pills and entecavir was su-perior to entecavir individually in the anti-liver fibrosis effect in patients with hepatitis B-related liver fibrosis.%目的:本研究以慢性乙型肝炎肝纤维化患者为研究对象,通过Fibroscan测得的肝脏弹性测定值评估鳖甲煎丸抗肝纤维化的疗效.方法:选取本院感染科门诊乙型肝炎肝纤维化患者47例,随机分为鳖甲煎丸联合恩替卡韦研究组与单用恩替卡韦对照组,分别收集两组患者治疗前后肝功能及肝脏弹性测定值(LSM)等资料进行统计分析和比较.结果:两组患者治疗后肝功能总胆红素(TBil)、白蛋白(ALB)及丙氨酸氨基转移酶(ALT)均较治疗前改善(P＜0.05),治疗后两组患者肝功能比较,差异无统计学意义(P＞0.05);两组患者治疗后LSM与本组治疗前比较,差异有统计意义(P＜0.05),治疗后研究组患者LSM下降程度优于对照组,差异有统计学意义(P＜0.05).结论:乙型肝炎肝纤维化患者应用鳖甲煎丸联合恩替卡韦,其抗肝纤维化作用优于单用恩替卡韦治疗.